Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxazosin SCHEMBL30772126 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL1648487 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL97513 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL29711371 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL29688095 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL29641831 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL8523145 | 0.99 | KMT2A (0.98) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL6479014 | 0.99 | KMT2A (0.98) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL612310 | 0.99 | KMT2A (0.98) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL5201447 | 0.97 | KMT2A (0.95) | KMT2AMMP1ADRB2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26599 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3426310-B1 | PROSTATIC LIQUID BIOPSY FOR THE DETECTION OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | WAVESENSE INC (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-12590181-B2 | Hydrophobically-modified associative thickener polymers process for the preparation and uses thereof | HERCULES LLC (US) | 2026-03-31 | — | — | US | claimed |
| WO-2026042047-A1 | COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-3930839-B1 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | CARDIFF ONCOLOGY INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4656194-A1 | COMPOSITION FOR PREVENTING OR TREATING POST-TRAUMATIC STRESS DISORDER, COMPRISING PHOSPHODIESTERASE TYPE 5 INHIBITOR AS ACTIVE INGREDIENT | Aribio Co., Ltd (KR) | 2025-12-03 | — | — | EP | claimed |
| EP-4192923-B1 | HYDROPHOBICALLY-MODIFIED ASSOCIATIVE THICKENER POLYMERS PROCESS FOR THE PREPARATION AND USES THEREOF | HERCULES LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| EP-0294993-A1 | A generic zero order controlled drug delivery system | PFIZER INC. (US) | 1988-12-14 | — | — | EP | claimed |
| US-4765989-A | SEMIPERMEABLE MATERIAL SURROUNDS COMPARTMENT | ALZA CORPORATION (US) | 1988-08-23 | — | — | US | claimed |
| US-4758569-A | Doxazosin as an anti-atherosclerosis agent | PFIZER INC. (US) | 1988-07-19 | — | — | US | claimed |
| EP-0271983-A1 | Transdermal flux enhancing compositions | PFIZER INC. (US) | 1988-06-22 | — | — | EP | claimed |
| EP-0259113-A2 | Controlled release device for an active substance | PFIZER INC. (US) | 1988-03-09 | — | — | EP | claimed |
| US-4659714-A | PROLONGATION WITH VASOCONSTRICTORS; REVERSAL WITH ADRENERGIC BLOCKING AGENTS | DENTSPLY, LTD. (GB) | 1987-04-21 | — | — | US | claimed |
| EP-0189336-A1 | Pharmaceutical compositions containing an alpha-blocker and a calcium antagonist | SYNTHELABO (FR) | 1986-07-30 | — | — | EP | claimed |
| EP-0160191-A1 | Kit for treating mammals | Dentsply Limited (GB) | 1985-11-06 | — | — | EP | claimed |
| US-4532135-A | Treating renal damage by administering vasodilator having postsynaptic alpha-adrenoceptor blocking activity and antihyperlipidemic characteristics | EDWARDS K DAVID G | 1985-07-30 | — | — | US | claimed |
| US-4188390-A | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines | PFIZER INC. (US) | 1980-02-12 | — | — | US | claimed |